Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins

Cancer Investigation

Volumn 29, Issue 9, 2011, Pages 585-593

  Chae, Young Kwang ^a,b   Valsecchi, Matias E ^b,c   Kim, Jongoh ^b,d   Bianchi, Anabella Lucca ^b   Khemasuwan, Danai ^b,e   Desai, Ajit ^b   Tester, William ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ACE inhibitors; Breast cancer; Cancer prevention; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; STATIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL HISTORY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT DURATION; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PENNSYLVANIA; RISK FACTORS; YOUNG ADULT;

EID: 80054848246     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.616252     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010 (March 20);28(9):1467-72.
3. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-2103. (Pubitemid 30225166)
4. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006;6:27.
5. Valsecchi ME, Pomerantz S, Jaslow R, Tester W. Reduced risk of bone metastasis for patients with breast cancer who used Cox-2 inhibitors. Clin Breast Cancer 2009;9(4):225-230.
6. Schmidt C. New studies support case for bisphosphonates as possible chemopreventive agent. J Natl Cancer Inst 2010;102(7): 453-455.
7. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic- Radisic V, SamoniggH, Tausch C, EidtmannH, Steger G, Kwasny W,DubskyP, FridrikM, Fitzal F, StiererM,Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360(7):679-691.
8. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005 (Feb);26(2):271-279. (Pubitemid 40253497)
9. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensinAT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002;294(2):441-447. (Pubitemid 34694114)
10. Rhodes D, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. PNAS 2009;106(25):10284-10289.
11. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factorand inflammation-related pathways. Lab Invest. 2002;82(6):747-756. (Pubitemid 34633824)
12. Suganuma T, Ino K, Shibata K, Kajiyama H,Nagasaka T,Mizutani S, Kikkawa F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005;11(7):2686-2694. (Pubitemid 40569470)
13. Ohnuma Y, Toda M, Fujita M, Hosono K, Suzuki T, Ogawa Y, Amano H, Kitasato H, Hayakawa K, Majima M. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother 2009;63(2):136-145.
14. Otake AH, Mattar AL, Freitas HC, Machado CM, Nonogaki S, Fujihara CK, Zatz R, Chammas R. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol 2010;66(1):79-87.
15. Rosenthal T, Gavras I. Angiotensin inhibition andmalignancies: a review. JHumHypertens 2009;23(10):623-635. Epub Apr 2, 2009.
16. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA. VATTC Trial: Association of ACE inhibitors and angiotensin randomized VATTC trial. J Natl Cancer Inst. 2008;100(17): 1223-1232.
17. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349(9051):525-528. (Pubitemid 27092790)
18. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352(9123):179-184. (Pubitemid 28327802)
19. Lang L. ACE inhibitors may reduce esophageal cancer incidence. Gastroenterology 2006;131(2):343-344. (Pubitemid 44142471)
20. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing 1st-line platinum-based chemotherapy. J Cancer Res ClinOncol 2009;135: 1429-1435.
21. Friis S, Sørensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, BlotWJ, Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001;92(9):2462-2470. (Pubitemid 33029093)
22. Coleman C, Baker W, Kluger J, White CM. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008;26(4):622-629. (Pubitemid 351354904)
23. Meier C, Derby L, Jick S, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000;160(3):349-353. (Pubitemid 30075217)
24. Koomen E, Herings R, Guchelaar H, Nijsten T. Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cancer Epidemiol 2009;33(5):391-395.
25. Chan K, OzaA, Siu L.Thestatins as anticancer agents. ClinCancer Res 2003;9:10-19.
26. Muck AO, Seeger H, Wallwiener D (2004) Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin PharmacolTher 42:695-700. (Pubitemid 39625129)
27. Keyomarsi, K., Sandoval, L, Band, V, and Pardee, AB. Synchronization of tumor and normal cells from G1 tomultiple cell cycles by lovastatin. Cancer Res 1991;51:3602-3609.
28. Agarwal, B, Bhendwal, S, Halmos, B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999;5:2223-2229. (Pubitemid 29399281)
29. Denoyelle, C, Vasse, M, Korner, M, Mishal Z, Ganné F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (Lond.) 2001;22: 1139-1148. (Pubitemid 32737327)
30. Graaf M, Richel D, van Noorden C, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004;30:609-641. (Pubitemid 39451828)
31. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143-148. (Pubitemid 32178190)
32. Kotamraju S, Willams C, Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginasedependent pathways. Cancer Res 2007;67(15):7386-7394. (Pubitemid 47206569)
33. Åberg M, Wickström M, Siegbahn A. Simvastatin induces apoptosis in human breast cancer cells in a NF?B dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa. Thromb Res 2008;122:191-202. (Pubitemid 351754915)
34. Koyuturk M, Ersoz M, Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett 2007;250:220-228. (Pubitemid 46529446)
35. Campbell MJ, Esserman LJ, Zhou Y, ShoemakerM, LoboM, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA,WintersM, Benz S, Benz CC. Breast cancer growth prevention by statins. Cancer Res 2006;66:8707-8714. (Pubitemid 44449187)
36. Kumar AS, Benz C, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 2008;17(5):1028-1033.
37. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56(3):280-285. (Pubitemid 36513491)
38. Boudreau DM, Gardner JS,Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzymeAinhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004;100(11): 2308-2316. (Pubitemid 38657877)
39. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004; 22(12):2388-2394. (Pubitemid 41115396)
40. Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004;90(3):635-637. (Pubitemid 38297203)
41. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23(34):8606-8612. (Pubitemid 46211502)
42. Eliassen AH, Colditz GA, Rosner B, WillettWC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med 2005;165(19):2264-2271. (Pubitemid 41549923)
43. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT, Women's Health Initiative Research Group. Statin use and breast cancer: prospective results from the Womens Health Initiative. J Natl Cancer Inst 2006;98(10):700-707. (Pubitemid 43821787)
44. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16(3):416-421. (Pubitemid 46548643)
45. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33. (Pubitemid 46058608)
46. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, EganKM. Statin use and risk of breast cancer.Cancer 2008;112:27-33.
47. Kwan M,Habel LA,Dawn Flick E,Quesenberry CP, Caan B. Postdiagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 2008;109:573-579. (Pubitemid 351698864)
48. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A,Theriault RL, Thor A, Weaver DL,Wieand HS, Greene FL. Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636. (Pubitemid 34983222)
49. Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC. ACE gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 2003;63:573-578. (Pubitemid 36158133)
50. KohWP,YuanJM, vandenBergD, SeowA, LeeHP,YuMC. Polymorphisms in angiontensin II type 1 receptor and ACE genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 2005;26:459-464. (Pubitemid 40246568)
51. González-Zuloeta Ladd AM, Arias Vásquez A, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O, Stricker B, van Duijn C. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14(9):2143-2146. (Pubitemid 41603259)
52. Yaren A, Turgut S, Kursunluoglu R, Oztop I, Turgut G, Degirmencioglu S, Kelten C, Erdem E. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with breast cancer and effects on prognostic factors. J InvestigMed 2007;55(5):255-261. (Pubitemid 47555944)